Comparing adaptive and non-adaptive algorithms for cancer early detection with novel biomarkers
- PMID: 17192068
- DOI: 10.3233/cbm-2006-23-407
Comparing adaptive and non-adaptive algorithms for cancer early detection with novel biomarkers
Abstract
It may be possible to reduce cancer mortality by monitoring the concentrations of serum biomarkers over time in men and women to detect their cancer early, when it is most curable. The simplest approach to using a biomarker for screening is to sequentially use fixed thresholds as a means to determine an abnormal test (e.g., PSA exceeding 4 mg/ml, CA 125 exceeding 30 U/ml). Alternatives to the simplest single threshold (ST) rules include more sophisticated algorithms that make use of screening history that accumulates over time and determines abnormal tests using individualized reference ranges. Although in principle longitudinal algorithms should out perform fixed threshold rules, the actual benefit gained will depend on behavior of the biomarker, the screening algorithm, and the screening frequency. Little information has been available to help predict when conditions should compel the adoption of the more sophisticated algorithms and when conditions suggest the simpler algorithms should suffice, or indeed be preferred. In this manuscript we evaluate the conditions under which one should expect great benefit, and when one should not expect benefit, by comparing the ability of simple and complex algorithms to detect cancer early under a variety of biomarker behaviors and screening frequencies.
Similar articles
-
Designing early detection programs for ovarian cancer.J Natl Cancer Inst. 2010 Jan 6;102(1):3-4. doi: 10.1093/jnci/djp450. Epub 2009 Dec 30. J Natl Cancer Inst. 2010. PMID: 20042718 Free PMC article. No abstract available.
-
SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other.Adv Exp Med Biol. 2008;622:15-21. doi: 10.1007/978-0-387-68969-2_2. Adv Exp Med Biol. 2008. PMID: 18546615 Review.
-
Generating longitudinal screening algorithms using novel biomarkers for disease.Cancer Epidemiol Biomarkers Prev. 2002 Feb;11(2):159-66. Cancer Epidemiol Biomarkers Prev. 2002. PMID: 11867503
-
A parametric empirical Bayes method for cancer screening using longitudinal observations of a biomarker.Biostatistics. 2003 Jan;4(1):27-40. doi: 10.1093/biostatistics/4.1.27. Biostatistics. 2003. PMID: 12925328
-
Early detection of ovarian cancer: promise and reality.Cancer Treat Res. 2002;107:61-97. doi: 10.1007/978-1-4757-3587-1_3. Cancer Treat Res. 2002. PMID: 11775462 Review. No abstract available.
Cited by
-
The role of biomarkers in the management of epithelial ovarian cancer.Expert Rev Mol Diagn. 2017 Jun;17(6):577-591. doi: 10.1080/14737159.2017.1326820. Epub 2017 May 15. Expert Rev Mol Diagn. 2017. PMID: 28468520 Free PMC article. Review.
-
Interpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk for ovarian cancer.Cancer Epidemiol Biomarkers Prev. 2012 Nov;21(11):2087-94. doi: 10.1158/1055-9965.EPI-12-0616. Epub 2012 Sep 7. Cancer Epidemiol Biomarkers Prev. 2012. PMID: 22962406 Free PMC article.
-
Longitudinal screening algorithm that incorporates change over time in CA125 levels identifies ovarian cancer earlier than a single-threshold rule.J Clin Oncol. 2013 Jan 20;31(3):387-92. doi: 10.1200/JCO.2012.43.6691. Epub 2012 Dec 17. J Clin Oncol. 2013. PMID: 23248253 Free PMC article.
-
Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA.Clin Cancer Res. 2008 May 1;14(9):2647-55. doi: 10.1158/1078-0432.CCR-07-1442. Clin Cancer Res. 2008. PMID: 18451228 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous